title: Effects of budesonide and probiotics enemas on the systemic inflammatory response of rats with experimental colitis.
abstract: OBJECTIVE
  The aim of this study was to investigate the effect of enemas containing probiotics and budesonide on the systemic inflammatory response in experimental colitis.
  
  
  METHODS
  Fifty male Wistar rats with experimental colitis induced by 10% acetic acid enema were randomized to five groups (10 rats each) according to the treatment: group 1--saline solution, group 2--budesonide (0.75 mg/kg/day), group 3--probiotics (1mg/day), group 4--probiotics plus budesonide, and group 5--control, with not-treated rats. The following variables were studied: body weight, serum levels of albumin, C-reactive protein and interleucine-6 (IL-6).
  
  
  RESULTS
  All animals lost weight between the beginning and the end of the experiment (280+ 16 mg versus 249+21 mg, p< 0.001). There was a significant decrease in the serum albumin between the normal pre-induction level (3.45 + 0.49 mg/dL) and the 1st day after colitis induction (1.61+051 mg/dL, p< 0.001) in all treated groups when compared to the control group. C- reactive protein increased after induction and diminished on the 7th day in all groups. In the control group there was an increase in the IL-6 after colitis induction. None of the treated groups significantly differed from IL-6 pre-colitis status (p>0.05). Only probiotic rats presented a significant decrease of IL-6 than controls (0,30+/-0,08 mg/dL vs. 0,19+/-0,03 mg/dL; p<0.01).
  
  
  CONCLUSIONS
  Probiotics are effective to diminished inflammatory status mediated by IL-6 in experimental colitis.
authors.affiliation: Department of Surgery, Federal University of Mato Grosso, 78045-390 Cuiabá, MT, Brazil.
authors.forename: Mardem Machado de
authors.initials: MM
authors.lastname: Souza
authors.forename: José Eduardo de
authors.initials: JE
authors.lastname: Aguilar-Nascimento
authors.forename: Diana Borges
authors.initials: DB
authors.lastname: Dock-Nascimento
mesh_terms: D000208:Acute Disease; D000209:Acute-Phase Proteins / Q000032:analysis; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001835:Body Weight; D019819:Budesonide / Q000008:administration & dosage*; D002097:C-Reactive Protein / Q000032:analysis; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004733:Enema; D015850:Interleukin-6 / Q000032:analysis; D008297:Male; D019936:Probiotics / Q000008:administration & dosage*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000032:analysis; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood
chemical_list: D000209:Acute-Phase Proteins; D000893:Anti-Inflammatory Agents; D015850:Interleukin-6; D012709:Serum Albumin; D019819:Budesonide; D002097:C-Reactive Protein